Selexis to develop CHO cell line for ASLAN's first biologic

By Dan Stanton contact

- Last updated on GMT

Image: iStock/janulla
Image: iStock/janulla

Related tags: Dna, Gene expression

ASLAN Pharmaceuticals has contracted Selexis to develop a CHO-K1 cell line to express its monoclonal antibody candidate targeting asthma.

Selexis will use its proprietary SUREtechnology ​to help yield a cell line for the expression of ASLAN004, the Singapore-based biopharma firm’s fully human blocking mAb currently in preclinical studies.

According to Selexis’ CEO Igor Fisch, the platform significantly improve efficacies throughout the biologic drug production process and has been used to develop cell lines for more than 70 programs in clinical development and one mAb in commercial product commercially available.

“The SUREtechnology Platform is comprised of a suite of innovative technologies that significantly improve efficacies throughout the biologic drug production process,”​ he told Biopharma-Reporter.com.

He added the platform’s foundation is the Selexis SGEs (Sure Genetic Elements) which “allow for vastly improved levels of stable recombinant gene transcription over many generations of cell division,” ​thus, producing elevated expression levels and more product.

“This also eliminates the need for gene amplification, thereby drastically reducing development timelines.”

Under the terms of the deal – of which financial details were not disclosed - Selexis will deliver a final clonal CHO-K1 cell line expressing ASLAN004, ASLAN ‘s first biologic candidate which the firm says has the potential to improve lung function and reduce exacerbations in a number of indications including moderate and severe asthma.

“Our partnership with Selexis allows us to leverage the company’s expertise and excellence in cell line generation as we seek to bolster the development of our proprietary biologics pipeline​,” said ASLAN’s COO Mark McHale.

Related topics: Pipelines, Bio Developments, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars